Alkeon Capital Management
MDGL icon

Alkeon Capital Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Alkeon Capital Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$43M Hold
80,000
– – 0.06% 90
2026
Q1 		$41.9M Sell
80,000
-160,000
-67% -$76.4M 0.07% 83
2025
Q4 		$140M Buy
240,000
+120,000
+100% +$61.3M 0.22% 66
2025
Q3 		$55M Buy
+120,000
New +$44.8M 0.08% 78

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Alkeon Capital Management's MDGL Position: Q2 2026 in Review

Alkeon Capital Management held its Madrigal Pharmaceuticals (MDGL) position steady in Q2 2026 at 80,000 shares worth $43M. The position accounts for 0.06% of the portfolio, ranked #90.

Alkeon Capital Management first reported a position in MDGL in Q3 2025 and has held it in 4 quarters since. The position peaked at $140M in Q4 2025. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Alkeon Capital Management held 80,000 shares of Madrigal Pharmaceuticals worth $43M as of Q2 2026.
  • Alkeon Capital Management left its Madrigal Pharmaceuticals share count unchanged in Q2 2026.
  • Madrigal Pharmaceuticals made up 0.06% of Alkeon Capital Management's portfolio in Q2 2026, its #90 holding.
  • Alkeon Capital Management first reported a position in Madrigal Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Alkeon Capital Management's Madrigal Pharmaceuticals position peaked at $140M in Q4 2025.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Alkeon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.